Winton Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.12M | Sell |
1,800
-12,978
| -88% | -$8.83M | 0.04% | 485 |
|
|
2026
Q1 | $11.4M | Buy |
14,778
+12,018
| +435% | +$9.2M | 0.4% | 46 |
|
|
2025
Q4 | $2.13M | Sell |
2,760
-1,559
| -36% | -$1.06M | 0.07% | 298 |
|
|
2025
Q3 | $2.43M | Buy |
4,319
+2,966
| +219% | +$1.68M | 0.09% | 255 |
|
|
2025
Q2 | $710K | Buy |
+1,353
| New | +$755K | 0.04% | 513 |
|
|
2025
Q1 | – | Sell |
-313
| Closed | -$223K | – | 775 |
|
|
2024
Q4 | $223K | Sell |
313
-755
| -71% | -$634K | 0.01% | 552 |
|
|
2024
Q3 | $1.12M | Buy |
+1,068
| New | +$1.19M | 0.08% | 228 |
|
|
2024
Q2 | – | Sell |
-4,664
| Closed | -$4.49M | – | 708 |
|
|
2024
Q1 | $4.49M | Sell |
4,664
-216
| -4% | -$205K | 0.32% | 57 |
|
|
2023
Q4 | $4.29M | Sell |
4,880
-1,040
| -18% | -$856K | 0.31% | 48 |
|
|
2023
Q3 | $4.87M | Sell |
5,920
-1,431
| -19% | -$1.12M | 0.4% | 37 |
|
|
2023
Q2 | $5.28M | Buy |
7,351
+2,766
| +60% | +$2.13M | 0.44% | 43 |
|
|
2023
Q1 | $3.77M | Sell |
4,585
-835
| -15% | -$630K | 0.23% | 73 |
|
|
2022
Q4 | $3.91M | Buy |
5,420
+2,143
| +65% | +$1.58M | 0.26% | 59 |
|
|
2022
Q3 | $2.26M | Sell |
3,277
-6,249
| -66% | -$3.93M | 0.15% | 172 |
|
|
2022
Q2 | $5.63M | Buy |
9,526
+2,822
| +42% | +$1.83M | 0.3% | 55 |
|
|
2022
Q1 | $4.68M | Buy |
6,704
+3,251
| +94% | +$2.06M | 0.25% | 75 |
|
|
2021
Q4 | $2.18M | Buy |
3,453
+431
| +14% | +$265K | 0.13% | 200 |
|
|
2021
Q3 | $1.83M | Buy |
3,022
+316
| +12% | +$196K | 0.1% | 224 |
|
|
2021
Q2 | $1.51M | Sell |
2,706
-962
| -26% | -$487K | 0.08% | 304 |
|
|
2021
Q1 | $1.74M | Sell |
3,668
-365
| -9% | -$178K | 0.1% | 196 |
|
|
2020
Q4 | $1.95M | Sell |
4,033
-7,151
| -64% | -$3.86M | 0.14% | 114 |
|
|
2020
Q3 | $6.26M | Sell |
11,184
-6,171
| -36% | -$3.74M | 0.2% | 72 |
|
|
2020
Q2 | $10.8M | Sell |
17,355
-1,282
| -7% | -$728K | 0.28% | 33 |
|
|
2020
Q1 | $9.1M | Buy |
18,637
+6,318
| +51% | +$2.61M | 0.24% | 78 |
|
|
2019
Q4 | $4.63M | Sell |
12,319
-59,977
| -83% | -$20.2M | 0.06% | 501 |
|
|
2019
Q3 | $20.1M | Buy |
72,296
+44,930
| +164% | +$13.3M | 0.24% | 137 |
|
|
2019
Q2 | $8.57M | Sell |
27,366
-15,423
| -36% | -$5.13M | 0.17% | 185 |
|
|
2019
Q1 | $17.6M | Buy |
42,789
+12,946
| +43% | +$5.33M | 0.35% | 103 |
|
|
2018
Q4 | $11.1M | Buy |
29,843
+15,802
| +113% | +$5.78M | 0.24% | 173 |
|
|
2018
Q3 | $5.67M | Buy |
+14,041
| New | +$5.34M | 0.12% | 267 |
|
|
2017
Q4 | – | Sell |
-11,543
| Closed | -$5.16M | – | 701 |
|
|
2017
Q3 | $5.16M | Buy |
11,543
+10,092
| +696% | +$4.8M | 0.16% | 152 |
|
|
2017
Q2 | $713K | Buy |
+1,451
| New | +$635K | 0.02% | 445 |
|
|
2014
Q3 | – | Sell |
-10,424
| Closed | -$2.94M | – | 679 |
|
|
2014
Q2 | $2.94M | Buy |
+10,424
| New | +$3.09M | 0.02% | 413 |
|
Other funds holding REGN
N
Winton Group's REGN Position: Q2 2026 in Review
Winton Group reduced its Regeneron Pharmaceuticals (REGN) stake by 88% in Q2 2026, selling an estimated $8.83M and leaving 1,800 shares worth $1.12M. The position accounts for 0.04% of the portfolio, ranked #485.
Winton Group first reported a position in REGN in Q2 2014 and has held it in 33 quarters since. The position peaked at $20.1M in Q3 2019. 917 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Winton Group held 1,800 shares of Regeneron Pharmaceuticals worth $1.12M as of Q2 2026.
- Winton Group sold 12,978 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.83M.
- Regeneron Pharmaceuticals made up 0.04% of Winton Group's portfolio in Q2 2026, its #485 holding.
- Winton Group first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 33 quarters since.
- Winton Group's Regeneron Pharmaceuticals position peaked at $20.1M in Q3 2019.
- 917 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.